Monitor for commercial partnership announcements or initial sales data from the UK market in upcoming quarters. The lack of disclosed revenue guidance or distribution agreements limits near-term revenue visibility.
Price Chart
Executive Summary
Pulsenmore announced MHRA registration for its Pulsenmore FC home ultrasound system, enabling marketing in the UK for IVF and fertility monitoring. This follows recent European MDR registration and marks the company's second product to reach international markets, expanding from pregnancy into broader women's health. The UK market represents over 100,000 fertility treatment cycles annually, but no revenue guidance or commercial agreements were disclosed.
Key Facts
- Pulsenmore FC received MHRA registration for marketing in the UK and Northern Ireland
- System enables home vaginal ultrasound for IVF/fertility patients to monitor follicular development and endometrial thickness
- UK market: ~53,000 IVF patients and >100,000 fertility treatment cycles in 2024
- This is Pulsenmore's second product to reach international markets, following its pregnancy monitoring system
- Registration follows recent European MDR registration
- No revenue guidance, commercial agreements, or pricing details provided
Financial Impact
No financial figures disclosed; regulatory milestone with no quantified revenue potential
Risk Factors
- No commercial agreements or revenue projections disclosed for the UK market
- Company has limited operating history and has not demonstrated ability to generate significant product revenue
- Forward-looking statements highlight risks including manufacturing, market penetration, and capital requirements
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-043034 |
| Exhibit: ex99-1.htm | 0001493152-26-043034 |
| Document: 0001493152-26-043034-index-headers.html | 0001493152-26-043034 |
| Document: 0001493152-26-043034-index.html | 0001493152-26-043034 |
| Document: 0001493152-26-043034.txt | 0001493152-26-043034 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 6-K | $1.90 | awaiting T+20 | — | $1.73 (−8.95%) |
Oct 8, 2026 18d ago | SC 13G | $1.85 | awaiting T+20 | — | $1.73 (−6.49%) |
Sep 17, 2026 5w ago | 6-K | $2.42 $1.81 | ▼ −25.21% | ▼ −26.41% | $1.73 (−28.51%) |
Sep 8, 2026 7w ago | 6-K | $2.46 $2.16 | ▼ −12.20% | ▼ −13.91% | $1.73 (−29.67%) |
Sep 2, 2026 7w ago | EFFECT | $2.55 $2.22 | ▲ +12.94% | ▲ +12.86% | $1.73 (+32.16%) |
Aug 31, 2026 8w ago | 6-K | $2.62 $2.19 | ▼ −16.41% | ▼ −16.22% | $1.73 (−33.97%) |
Aug 19, 2026 9w ago | 6-K | $3.01 $2.42 | ▼ −19.60% | ▼ −18.76% | $1.73 (−42.52%) |
Aug 17, 2026 10w ago | 6-K | $2.89 $2.41 | ▼ −16.61% | ▼ −14.63% | $1.73 (−40.14%) |
Jul 13, 2026 15w ago | 6-K | $3.62 $3.26 | ▼ −9.94% | ▼ −13.13% | $1.73 (−52.21%) |
Jul 13, 2026 15w ago | EFFECT | $3.62 $3.26 | ▼ −9.94% | ▼ −13.13% | $1.73 (−52.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers